Transcutaneous electrical nerve stimulation for pain management during intrauterine device insertion: a randomized controlled trial
Related Experiment Video
Updated: Oct 10, 2026

An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)
Published on: January 27, 2010
Lauren H Kus1, Catherine R Statis1, Meghana Kudrimoti2
1Division of Complex Family Planning, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY.
Background:
Pain during intrauterine device insertion is a significant patient concern. Current pharmacologic strategies inadequately address procedural pain, highlighting the need for a rigorous evaluation of novel approaches.
Objective:
To evaluate whether high-frequency transcutaneous electrical nerve stimulation reduces pain with intrauterine device insertion.
Study Design:
We conducted a double-blind randomized controlled trial in which 98 participants undergoing levonorgestrel 52 mg or copper 380 mm2 intrauterine device insertion received either active high-frequency transcutaneous electrical nerve stimulation or sham transcutaneous electrical nerve stimulation. We measured pain using a 100-mm visual analog scale at multiple timepoints during the procedure. The primary outcome was pain at the time of intrauterine device insertion. Participants completed a preprocedure survey asking about demographic and reproductive characteristics, anticipated pain, and anxiety. We asked participants after the procedure about satisfaction with pain during procedure and the transcutaneous electrical nerve stimulation device. Clinicians completed a postprocedure survey asking about their perception of participant pain and ease of insertion. We estimated a total sample size of 98 to achieve 80% power to detect a 20 mm difference in pain scores, with 10% attrition or protocol deviation and 15% inflation to account for nonparametric distribution. We performed an intention-to-treat analysis and calculated mean pain scores and standard deviations. We used t-tests to compare mean pain scores at the time of intrauterine device insertion and chi-square tests to compare categorical variables. We dichotomized parity as nulliparous (no prior delivery) vs parous (any delivery >20 weeks).
Results:
Between March 2024 and April 2025, we screened 150 participants and enrolled 99 individuals (active n=49; sham n=50) with 1 postrandomization exclusion. Baseline characteristics were similar, with a median age of 29 years and just over half having had a previous birth (53.1%). Pain at the time of intrauterine device insertion did not differ between active and sham transcutaneous electrical nerve stimulation groups (50.8±26.9 mm vs 50.6±29.2 mm; P=.97). We also observed no differences in procedure duration. Nulliparous participants reported higher pain scores overall compared with parous individuals, but we detected no difference in pain scores relative to treatment intervention within groups (nulliparous - active 58.8±28.7 mm, sham 59.3±25.5 mm, P=.95; parous - active 43.5±23.3 mm vs sham 43.2±30.6, P=.97). Although clinician estimates and participant-reported maximum-pain scores were mildly correlated (Pearson correlation coefficient = 0.41), there was a significant difference between mean clinician-estimated and participant-reported maximum pain scores (P<.001), 48.9±26.8 mm vs 60.5±25.2 mm, respectively. Participants undergoing intrauterine device insertions perceived as difficult by clinicians reported higher mean pain scores than those perceived as easy (71.6±24.2 mm vs 56.0±24.4 mm, respectively; P=.006).
Conclusion:
High-frequency active transcutaneous electrical nerve stimulation did not reduce pain during intrauterine device insertion compared with sham transcutaneous electrical nerve stimulation. These findings were not affected by parity.
